title: New treatments for chronic lymphocytic leukemia.
abstract: An enhanced understanding of the important pathways governing chronic lymphocytic leukemia (CLL) cell survival and the critical role played by the microenvironment in the pathogenesis of the disease has brought new opportunities for drug development in CLL. Several new targets have been identified, and novel agents are under intense investigation in clinical trials. Some of these agents are already demonstrating promising anti-CLL activity on their own, whereas others hold promise in combination with existing therapeutic options. As the use of monoclonal antibodies for chemoimmunotherapy becomes standard clinical practice, the future holds promise for concurrent targeting of the tumor cell as well as its microenvironment.
authors: Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org
authors: Asher A
authors: AA
authors: Chanan-Khan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
references: Drugs. 2003;63(10):953-69
references: 12699399
references: N Engl J Med. 2006 Oct 5;355(14):1456-65
references: 17021321
references: Blood. 2004 May 1;103(9):3278-81
references: 14726385
references: J Clin Oncol. 2007 Mar 20;25(9):1114-20
references: 17296974
references: Leuk Lymphoma. 2004 Jan;45(1):79-84
references: 15061201
references: J Clin Oncol. 2006 Dec 1;24(34):5343-9
references: 17088571
references: Leuk Lymphoma. 1996 Jun;22(1-2):83-90, follow. 186, color plate VI
references: 8724532
references: Br J Cancer. 2005 Sep 19;93(6):613-9
references: 16222306
references: Blood. 2003 Jan 1;101(1):6-14
references: 12393429
references: Blood. 2005 Jan 1;105(1):49-53
references: 15138165
references: Blood. 2005 Oct 1;106(7):2506-12
references: 15972449
references: Blood Rev. 1990 Sep;4(3):165-74
references: 2245252
references: Lancet Oncol. 2006 Jun;7(6):480-8
references: 16750498
references: Histol Histopathol. 1998 Apr;13(2):521-30
references: 9589906
references: Blood. 2000 Oct 15;96(8):2655-63
references: 11023495
references: Blood. 2007 Jan 15;109(2):405-11
references: 17008537
references: Leuk Res. 2005 Nov;29(11):1253-7
references: 15916806
references: Haematologica. 2005 Oct;90(10):1357-64
references: 16219572
references: Clin Cancer Res. 2005 Jun 1;11(11):4176-81
references: 15930354
references: Blood. 2005 Oct 1;106(7):2513-9
references: 15972445
references: J Clin Oncol. 2003 Apr 1;21(7):1278-84
references: 12663715
references: J Clin Oncol. 2005 Oct 20;23(30):7697-702
references: 16186597
references: J Clin Oncol. 2005 Jun 20;23(18):4070-8
references: 15767647
references: J Clin Oncol. 2005 Jun 20;23(18):4079-88
references: 15767648
references: Microvasc Res. 2005 Jan;69(1-2):56-63
references: 15797261
references: Blood. 2005 Nov 15;106(10):3348-52
references: 16051743
references: Blood. 2007 Jan 15;109(2):399-404
references: 17003373
references: J Clin Oncol. 2006 Apr 1;24(10):1575-81
references: 16520464
references: Blood. 1996 Jun 15;87(12):4990-7
references: 8652811
references: Blood. 2006 Nov 15;108(10):3458-64
references: 16840727
references: Blood. 2000 Jul 15;96(2):393-7
references: 10887097
references: Med Oncol. 2005;22(3):291-302
references: 16110140
references: Exp Hematol. 2003 Mar;31(3):185-90
references: 12644014
references: Hematol J. 2004;5(1):47-54
references: 14745430
references: Semin Hematol. 1993 Oct;30(4):306-17
references: 7505482
references: Crit Rev Oncol Hematol. 2001 May;38(2):139-70
references: 11311660
references: Leukemia. 2002 May;16(5):911-9
references: 11986954